Benitec Biopharma (BNTC) Revenue (2019 - 2023)

Benitec Biopharma has disclosed Revenue across 5 years of filings, most recently posting $7000.0 for Q2 2023.

• Revenue for Q2 2023 came in at $7000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2024 was $7000.0 (down 89.71% YoY), and the FY2023 annual result was $75000.0, up 2.74% from the prior year.
• Revenue came in at $7000.0 for Q2 2023 at Benitec Biopharma, down from $54000.0 in the prior quarter.
• In the past five years, Revenue ranged from a high of $77000.0 in Q4 2019 to a low of -$35000.0 in Q2 2020.
• The 5-year median for Revenue is $25000.0 (2021), against an average of $23846.2.
• Across the five-year window, Revenue tumbled 98.7% in 2020 and soared 4700.0% in 2022, its largest moves.
• Benitec Biopharma's Revenue stood at $77000.0 in 2019, then sank by 98.7% to $1000.0 in 2020, then surged by 2400.0% to $25000.0 in 2021, then slumped by 44.0% to $14000.0 in 2022, then slumped by 50.0% to $7000.0 in 2023.
• The last three Revenue figures came in at $7000.0 (Q2 2023), $54000.0 (Q1 2023), and $14000.0 (Q4 2022), per Business Quant data.